#AHA19 – Randomized Trial: Phosphodiesterase 5 inhibitor Improves Exercise Capacity in Patients Who Have Undergone the Fontan Procedure
19 Nov, 2019 | 08:45h | UTCResults of the Fontan Udenafil Exercise Longitudinal (FUEL) Trial – Circulation (free for a limited period)
Commentaries: Teens with Heart Disease Improve Exercise Capacity in Large Clinical Trial – Children’s Hospital of Philadelphia (free) AND Pediatric drug trial finds benefit in teens with heart defect – NIH News Releases (free)
#AHA19 – Just Presented at the 2019 American Heart Association Annual Meeting
Related Commentary on Twitter
FUEL Trial- udenafil did not improve peak VO2, but did positively impact measures of exercise performance in pts w/FONTAN @PHNresearch @nih_nhlbi @HeartCare4Kids @ChildrensPhila #CircAHA19 #AHA19 #AHAJournals https://t.co/Kmt9GFASZR pic.twitter.com/WV0NITTg7y
— Circulation (@CircAHA) November 17, 2019